Provectus Biopharma Files Q1 2025 10-Q
Ticker: PVCT · Form: 10-Q · Filed: May 14, 2025 · CIK: 315545
| Field | Detail |
|---|---|
| Company | Provectus Biopharmaceuticals, Inc. (PVCT) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biopharmaceutical
Related Tickers: PVCT
TL;DR
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) filed its Q1 2025 10-Q. Financials are in.
AI Summary
Provectus Biopharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quarter of 2025. Key financial data and disclosures related to its pharmaceutical preparations business are presented.
Why It Matters
This filing provides investors with an update on Provectus Biopharmaceuticals' financial health and operational status for the first quarter of 2025, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Provectus faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- Q1 2025 — Reporting Period (The period covered by this 10-Q filing.)
- 2025-03-31 — As of Date (The specific date for which financial information is reported.)
Key Players & Entities
- PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250514 (date) — Filing date
- PHARMACEUTICAL PREPARATIONS [2834] (industry) — Company's Standard Industrial Classification
FAQ
What is the primary business of Provectus Biopharmaceuticals, Inc.?
Provectus Biopharmaceuticals, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 14, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What are some of the preferred stock types mentioned in relation to the company's capital structure?
The filing mentions Series D Convertible Preferred Stock and Series D-One Convertible Preferred Stock.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).